Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Antithrombotic Effect of Artemisinin through Phosphoprotein Regulation in U46619-induced Platelets

  • Dong-Ha Lee (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
  • Received : 2023.08.21
  • Accepted : 2023.09.18
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Normal activation of platelets and their aggregation are crucial during hemostasis process. It appears excessive or abnormal aggregation of platelets may bring about cardiovascular diseases like stroke, atherosclerosis, and thrombosis. For this reason, finding a substance that can regulate platelet aggregation or suppress aggregation will aid in the prevention and treatment of cardiovascular diseases. Artemisinin, a compound derived from Artemisia or Scopolia plants, has shown potential in various areas such as anticancer and Alzheimer's disease research. However, the specific role and mechanisms by which artemisinin influences platelet activation and thrombus formation are not yet fully understood. This study investigated the effects of artemisinin on platelet activation and thrombus formation. This study examined the effect of artemisinin on regulation of U46619-induced platelet aggregation, granule secretion. In addition, the effects of artemisinin on phosphorylation of PI3K/Akt and MAPK pathway involved in platelet aggregation was studied. As a result, artemisinin significantly downregulated of PI3K/Akt and MAPK pathway. In addition, artemisinin significantly reduced granule secretion, and platelet aggregation was inhibited by artemisinin. Therefore, we suggest that artemisinin is an anti-platelet substance that regulates PI3K/Akt and MAPK pathway and is valuable as a therapeutic and preventive agent for platelet-derived cardiovascular disease.

Keywords

Acknowledgement

Funding for this paper was provided by Namseoul University year 2023.

References

  1. Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ. Platelet JNK1 is involved in secretion and thrombus formation. Blood. 2010. 115: 4083-4092. https://doi.org/10.1182/blood-2009-07-233932
  2. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, Sage T, Stanley RG, Tucker KL, Wright B, Gibbins JM. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008. 154: 918-939. https://doi.org/10.1038/bjp.2008.151
  3. Bassand JP. Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. Int J Cardiol. 2013. 163: 5-18. https://doi.org/10.1016/j.ijcard.2011.10.104
  4. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood. 1999. 94: 3800-3805. https://doi.org/10.1182/blood.V94.11.3800
  5. Calderwood DA. Integrin activation. J Cell Sci. 2004. 117: 657-666. https://doi.org/10.1242/jcs.01014
  6. Chuang WY, Kung PH, Kuo CY, Wu CC. Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidy-linositol 3-kinase/Akt pathway. Thromb Haemost. 2013. 109: 1120-1130. https://doi.org/10.1160/TH12-09-0636
  7. Das SS, Nanda GG, Alone DP. Artemisinin and curcumin inhibit Drosophila brain tumor, prolong life span, and restore locomotor activity. IUBMB Life. 2014. 66: 496-506. https://doi.org/10.1002/iub.1284
  8. Fang J, Zhao X, Li S, Xing X, Wang H, Lazarovici P, et al. Protective mechanism of artemisinin on rat bone marrow-derived mesenchymal stem cells against apoptosis induced by hydrogen peroxide via activation of c-Raf-Erk1/2-p90(rsk)-CREB pathway. Stem Cell Research & Therapy. 2019. 10: 312.
  9. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood. 2009. 113: 893-901. https://doi.org/10.1182/blood-2008-05-155978
  10. Kramer RM, Roberts EF, Strifler BA, Johnstone EM. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem. 1995. 270: 27395-27398. https://doi.org/10.1074/jbc.270.46.27395
  11. Lee DS, Kim TH, Jung YS. Inhibitory effect of allyl isothiocyanate on platelet aggregation. J Agric Food Chem. 2014. 62: 7131-7139. https://doi.org/10.1021/jf4041518
  12. Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett. 2002. 531: 475-482. https://doi.org/10.1016/S0014-5793(02)03587-1
  13. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994. 330: 1287-1294. https://doi.org/10.1056/NEJM199405053301808
  14. Peng T, Li S, Liu L, Yang C, Farhan M, Chen L, Su Q, Zheng W. Artemisinin attenuated ischemic stroke induced cell apoptosis through activation of ERK1/2/CREB/BCL-2 signaling pathway in vitro and in vivo. Int J Biol Sci. 2022. 18: 4578-4594. https://doi.org/10.7150/ijbs.69892
  15. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002. 8: 1227-1234. https://doi.org/10.1038/nm1102-1227
  16. Vaiyapuri S, Ali MS, Moraes LA, Sage T, Lewis KR, Jones CI, Gibbins JM. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling. Arterioscler Thromb Vasc Biol. 2013. 33: 2740-2749. https://doi.org/10.1161/ATVBAHA.113.301988
  17. Wang KS, Li J, Wang Z, Mi C, Ma J, Piao LX, et al. Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways. Immunopharmacol Immunotoxicol. 2017. 39: 28-36. https://doi.org/10.1080/08923973.2016.1267744
  18. Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF. Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. Med Res Rev. 2017. 37: 1492-1517. https://doi.org/10.1002/med.21446
  19. Xia Q, Wang X, Xu DJ, Chen XH, Chen FH. Inhibition of platelet aggregation by curdione from Curcuma wenyujin essential Oil. Thromb Res. 2012. 130: 409-414. https://doi.org/10.1016/j.thromres.2012.04.005
  20. Xu G, Huang YL, Li PL, Guo HM, Han XP. Neuroprotective effects of artemisinin against isoflurane-induced cognitive impairments and neuronal cell death involve JNK/ERK1/2 signalling and improved hippocampal histone acetylation in neonatal rats. The Journal of Pharmacy and Pharmacology. 2017. 69: 684-697. https://doi.org/10.1111/jphp.12704
  21. Yao Y, Guo Q, Cao Y, Qiu Y, Tan R, Yu Z. Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer. J Exp Clin Cancer Res. 2018. 37: 282.
  22. Zeng Z, Xu J, Zheng W. Artemisinin protects PC12 cells against beta-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol. 2017. 12: 625-633. https://doi.org/10.1016/j.redox.2017.04.003
  23. Zhao X, Fang J, Li S, Gaur U, Xing X, Wang H. Artemisinin Attenuated Hydrogen Peroxide (H2O2)-Induced Oxidative Injury in SH-SY5Y and Hippocampal Neurons via the Activation of AMPK Pathway. Int J Mol Sci. 2019. 20: 2680.